Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
SourceBlood Advances, 5, 4, (2021), pp. 1110-1121
Article / Letter to editor
Display more detailsDisplay less details
SubjectAll institutes and research themes of the Radboud University Medical Center; Radboudumc 5: Inflammatory diseases RIHS: Radboud Institute for Health Sciences
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.